External evaluation of the predictive performance of published population pharmacokinetic models of linezolid in adult patients

被引:1
|
作者
Qin, Yan [1 ]
Jiao, Zheng [2 ]
Ye, Yan-Rong [1 ]
Shen, Yun [1 ]
Chen, Zhe [1 ]
Chen, Yue-Ting [2 ]
Li, Xiao-Yu [1 ]
Lv, Qian-Zhou [1 ,3 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Pharm, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pharm, Shanghai, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Dept Pharm, 180 Fenglin Rd, Shanghai 200032, Peoples R China
关键词
Linezolid; Population pharmacokinetics; External evaluation; NONMEM; CRITICALLY-ILL PATIENTS; BODY-WEIGHT; PHARMACODYNAMICS; EQUATION; DISEASE; PROFILE; PLASMA; TARGET; FLUID; FOCUS;
D O I
10.1016/j.jgar.2023.08.003
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: Several linezolid population pharmacokinetic (popPK) models have been established to facilitate optimal therapy; however, their extrapolated predictive performance to other clinical sites is unknown. This study aimed to externally evaluate the predictive performance of published pharmacokinetic models of linezolid in adult patients.Methods: For the evaluation dataset, 150 samples were collected from 70 adult patients (72.9% of which were critically ill) treated with linezolid at our center. Twenty-five published popPK models were identified from PubMed and Embase. Model predictability was evaluated using prediction-based, simulationbased, and Bayesian forecasting-based approaches to assess model predictability. Results: Prediction-based diagnostics found that the prediction error within +/- 30% (F 30 ) was less than 40% in all models, indicating unsatisfactory predictability. The simulation-based prediction- and variabilitycorrected visual predictive check and normalized prediction distribution error test indicated large discrepancies between the observations and simulations in most of the models. Bayesian forecasting with one or two prior observations significantly improved the models' predictive performance. Conclusion: The published linezolid popPK models showed insufficient predictive ability. Therefore, their sole use is not recommended, and incorporating therapeutic drug monitoring of linezolid in clinical applications is necessary.(c) 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:347 / 353
页数:7
相关论文
共 50 条
  • [41] Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia
    Xie, Feifan
    Mantzarlis, Konstantinos
    Malliotakis, Polychronis
    Koulouras, Vasileios
    Degroote, Sophie
    Koulenti, Despoina
    Blot, Stijn
    Boussery, Koen
    Van Bocxlaer, Jan
    Colin, Pieter
    Zakynthinos, Epameinondas
    Georgopoulos, Dimitrios
    Papathanasiou, Athanasios
    Arvaniti, Kostoula
    Matamis, Dimitrios
    Spring, Anna
    Bekos, Vasileios
    Komnos, Apostolos
    Zafeiridis, Tilemachos
    Vogelaers, Dirk
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (03) : 667 - 674
  • [42] Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation
    Soraluce, Amaia
    Barrasa, Helena
    Asin-Prieto, Eduardo
    Angel Sanchez-Izquierdo, Jose
    Maynar, Javier
    Isla, Arantxazu
    Rodriguez-Gascon, Alicia
    PHARMACEUTICS, 2020, 12 (01)
  • [43] Linezolid dosing in critically ill patients undergoing various modalities of renal replacement therapy: a pooled population pharmacokinetic analysis
    Liu, Qian
    Li, Sanwang
    Xie, Feifan
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023, 62 (04)
  • [44] Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients
    Cojutti, Piergiorgio
    Pai, Manjunath P.
    Pea, Federico
    CLINICAL PHARMACOKINETICS, 2018, 57 (08) : 989 - 1000
  • [45] Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy
    Byrne, C. J.
    Roberts, J. A.
    McWhinney, B.
    Ryder, S. A.
    Fennell, J. P.
    O'Byrne, P.
    Deasy, E.
    Egan, S.
    Desmond, R.
    Enright, H.
    D'Arcy, D. M.
    McHugh, J.
    CLINICAL MICROBIOLOGY AND INFECTION, 2017, 23 (09) : 674.e7 - 674.e13
  • [46] External validation of population pharmacokinetic models of vancomycin in postoperative neurosurgical patients
    Wei, Shifeng
    Chen, Jingcheng
    Zhao, Zhigang
    Mei, Shenghui
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (08) : 1031 - 1042
  • [47] Prolonged infusion of linezolid is associated with improved pharmacokinetic/pharmacodynamic (PK/PD) profiles in patients with external ventricular drains
    Zhao, Wenjun
    Kong, Lingti
    Wu, Chenchen
    Wu, Xiaofei
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (01) : 79 - 86
  • [48] Population Pharmacokinetic Evaluation with External Validation of Tacrolimus in Chinese Primary Nephrotic Syndrome Patients
    Lin Yang
    Nan Yang
    Bin Yi
    Qi Pei
    Zhijun Huang
    Pharmaceutical Research, 2022, 39 : 1907 - 1920
  • [49] Population Pharmacokinetic Evaluation with External Validation of Tacrolimus in Chinese Primary Nephrotic Syndrome Patients
    Yang, Lin
    Yang, Nan
    Yi, Bin
    Pei, Qi
    Huang, Zhijun
    PHARMACEUTICAL RESEARCH, 2022, 39 (08) : 1907 - 1920
  • [50] External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients
    Yang, Yunyun
    Wang, Chenyu
    Chen, Yueting
    Wang, Xuebin
    Jiao, Zheng
    Wang, Zhuo
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 186